| Project/Area Number |
23659787
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | International University of Health and Welfare |
|---|
Principal Investigator |
MAKOTO EMOTO 国際医療福祉大学, 保健医療学部, 教授 (80258540)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 癌幹細胞 / ミューラー管腫瘍 / 子宮癌肉腫 / CD133 / PAX2 / 血管新生 / VEGF / ミューラー管悪性腫瘍 / 間葉系幹細胞 / FU-MMT-1 / SOX2 / 子宮肉腫 / Angiopoietin / 超音波 / がん幹細胞 / ミューラー管 / 婦人科腫瘍 / Oct4 / Wnt4 / 婦人科癌 / 4-Oct |
|---|
| Outline of Final Research Achievements |
The biological characteristics of malignant Mullerian tumors (Uterine carcinosarcomas) are still unclear. We identified the cancer stem cells in this tumor by using FU-MMT-1 cells, which was established by our own from human uterine carcinosarcoma (Emoto M. Cancer 1992). These cancer stem cells in FU-MMT-1 significantly expressed OCT4, NANOG, SOX2, C-MYC, BMI-1 as well as the Mullerian gene, PAX2 and WNT-4. The CD133 positive FU-MMT-1 cells also possessed high angiogenic activity (high expression of VEGF-A), thus, the anti-angiogenic therapy might be expected as a new therapeutic strategy for these tumors.
|
